Gastropathy Due to Celecoxib, a Cyclooxygenase-2 Inhibitor

Mohammed, Suneel; Croom, Dorwyn W.

doi:10.1056/nejm199906243402516

Cited by 36 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the use of higher-cost selective cyclooxygenase-2 inhibitors (COX-2) has been promoted due to the lower incidence of gastrointestinal events compared to non-selective cyclooxygenase inhibitors such as naproxen [18]. However, increasing evidence indicates that COX-2 inhibitors may also be associated with acute gastrointestinal events [19]. Furthermore, no significant benefits were demonstrated in a recent randomized study comparing the use of etodolac (COX-2 inhibitor) versus diclofenac (non-selective inhibitor) after CABG [11].…”

Section: Discussionmentioning

confidence: 99%

Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial

Kulik

Ruel

Bourke

et al. 2004

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial

Kulik

Ruel

Bourke

et al. 2004

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…Although the COX-2 inhibitors are beneficial for many patients, gastrointestinal-related side effects may occur. 6 A case of a possible celecoxibinduced gastroduodenal ulceration after twicedaily administration for 4 months was reported. 5 Another report described hematemesis and melena after 3 weeks of rofecoxib therapy in a patient who previously tolerated conventional NSAIDs.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Bleeds Associated with Rofecoxib

Foral¹,

Wilson²,

Nystrom³

2002

Pharmacotherapy

View full text Add to dashboard Cite

Data suggest that cyclooxygenase (COX)-2 inhibitors are safer for the gastrointestinal tract than traditional nonsteroidal antiinflammatory drugs (NSAIDs). Rofecoxib, a COX-2-specific NSAID, does not inhibit the COX-1 enzyme, thereby decreasing the potential for gastrointestinal-related adverse effects. Patients who are at an increased risk for NSAID-related gastrointestinal bleeding are therefore appropriate candidates for COX-2 inhibitors. Although the agents provide benefits for many patients, gastrointestinal-related side effects may occur, and caution should be practiced when prescribing COX-2 inhibitors. We report two patients who were admitted to the hospital with diagnoses of gastrointestinal bleeds while they were taking rofecoxib.

show abstract

“…The incidence of reactive gastropathy has been estimated to be between one third and one half of patients taking NSAIDs [27]. At present, there is insufficient evidence to determine whether or not the use of selective COX2 inhibitors results in decreased reactive gastropathy, although reports of such an association do exist [28].…”

Section: Reactive Gastropathy 241 Nonsteroidal Anti-inflammatory Dmentioning

confidence: 99%